These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37985959)

  • 1. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
    Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
    J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma.
    Sae-Fung A; Mutirangura A; Jitkaew S
    Front Immunol; 2022; 13():1051273. PubMed ID: 36733386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma.
    Cao Z; Zeng L; Wang Z; Wen X; Zhang J
    Funct Integr Genomics; 2023 May; 23(2):190. PubMed ID: 37247093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
    Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
    Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
    Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
    Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
    Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
    Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.
    Lin J; Dai Y; Sang C; Song G; Xiang B; Zhang M; Dong L; Xia X; Ma J; Shen X; Ji S; Zhang S; Wang M; Fang H; Zhang X; Wang X; Zhang B; Zhou J; Fan J; Zhou H; Gao D; Gao Q
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteogenomic characterization of cholangiocarcinoma.
    Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
    Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
    Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
    PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The construction of a prognostic model by apoptosis-related genes to predict survival, immune landscape, and medication in cholangiocarcinoma.
    Shen P; Shi Y; Xu P; Rao L; Wang Z; Jiang J; Weng M
    Clin Res Hepatol Gastroenterol; 2024 Oct; 48(8):102430. PubMed ID: 39069260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma.
    Liu Q; Zhu J; Huang Z; Zhang X; Yang J
    Technol Cancer Res Treat; 2024; 23():15330338241239139. PubMed ID: 38613350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophages-aPKC
    Yang T; Deng Z; Xu L; Li X; Yang T; Qian Y; Lu Y; Tian L; Yao W; Wang J
    J Exp Clin Cancer Res; 2022 Jan; 41(1):23. PubMed ID: 35033156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of microRNA-203 in cholangiocarcinoma.
    Li J; Gao B; Huang Z; Duan T; Li D; Zhang S; Zhao Y; Liu L; Wang Q; Chen Z; Cheng K
    Int J Clin Exp Pathol; 2015; 8(8):9512-6. PubMed ID: 26464713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.